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Background: The kidneys are a principal dose-limiting organ in radiotherapy for upper abdominal cancers. The
current understanding of kidney radiation dose response is rudimentary. More precise dose-volume response
models that allow direct correlation of delivered radiation dose with spatio-temporal changes in kidney function
may improve radiotherapy treatment planning for upper-abdominal tumours.
Our current understanding of kidney dose response and tolerance is limited and this is hindering efforts to introduce
advanced radiotherapy techniques for upper-abdominal cancers, such as intensity-modulated radiotherapy (IMRT). The
aim of this study is to utilise radiotherapy and combined anatomical/functional imaging data to allow direct correlation of
radiation dose with spatio-temporal changes in kidney function. The data can then be used to develop a more precise
dose-volume response model which has the potential to optimise and individualise upper abdominal radiotherapy plans.
Methods/design: The Radiotherapy of Abdomen with Precise Renal Assessment with SPECT/CT Imaging (RAPRASI) is an
observational clinical research study with participating sites at Sir Charles Gairdner Hospital (SCGH) in Perth, Australia and
the Peter MacCallum Cancer Centre (PMCC) in Melbourne, Australia. Eligible patients are those with upper gastrointestinal
cancer, without metastatic disease, undergoing conformal radiotherapy that will involve incidental radiation to one or
both kidneys. For each patient, total kidney function is being assessed before commencement of radiotherapy treatment
and then at 4, 12, 26, 52 and 78 weeks after the first radiotherapy fraction, using two procedures: a Glomerular Filtration
Rate (GFR) measurement using the 51Cr-ethylenediamine tetra-acetic acid (EDTA) clearance; and a regional kidney
perfusion measurement assessing renal uptake of 99mTc-dimercaptosuccinic acid (DMSA), imaged with a Single Photon
Emission Computed Tomography / Computed Tomography (SPECT/CT) system. The CT component of the SPECT/CT
provides the anatomical reference of the kidney’s position. The data is intended to reveal changes in regional kidney
function over the study period after the radiotherapy. These SPECT/CT scans, co-registered with the radiotherapy
treatment plan, will provide spatial correlation between the radiation dose and regional renal function as assessed by
SPECT/CT. From this correlation, renal response patterns will likely be identified with the purpose of developing a
predictive model.
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Radiotherapy has a significant role to play in the man-
agement of cancers of the upper abdomen, but high dose
radiotherapy has been considerably limited by potential
adverse normal tissue responses, in particular that of the
kidneys. Because of their proximity to organs such as the
pancreas, stomach and oesophagus, incidental radiation
dose to the kidneys is frequently unavoidable when plan-
ning radiotherapy treatment. Our current understanding
of kidney dose response and tolerance to radiation is rudi-
mentary. This limits the delivery of a higher dose to the
tumour and also the introduction and optimisation of new
techniques to treat these upper gastrointestinal cancers,
such as intensity modulated radiation therapy (IMRT).
Until recently, estimation of radiation-induced kidney
damage was based on analysis of very basic radiotherapy
data by Emami et al [1]. The Quantitative Analyses of
Normal Tissue Effects in the Clinic (QUANTEC) review
collated results of relevant studies that have been under-
taken so far [2]. There have been previous key studies that
have addressed the effects of partial kidney irradiation. In
1973, Thompson et al [3] reported the occurrence of clin-
ical kidney toxicity several years after radiotherapy. Willet
et al [4] found a dependence on the percentage of the vol-
ume being irradiated with a decrease in creatinine clear-
ance. More recently, Kost et al [5] in 2002, used sequential
scintigraphy to assess impairment of renal function and
correlated it with the radiation dose distribution. Jansen
et al [6] observed a progressive decrease in renal function
in gastric cancer patients after postoperative radiotherapy.
Studies in pigs [7,8] have shown that the response is de-
pendent on whether one or both kidneys are irradiated
and that the functional response depends on the compen-
satory response of the non-irradiated kidney.
A review of the preceding studies and the QUANTEC
report [2] has highlighted several key points which have
influenced the design of the RAPRASI study protocol:
– Kidneys have a late response to radiation (between 3
and 18 months).
– The functional response is dependent on the
percentage of the kidney volume being irradiated
and the dual nature of this organ influences their
response.
– There is limited quantitative data to support dose-
volume models for the kidney. Studies are required
with collection of data that would allow correlating
regional kidney function over time with theradiation dose distribution received in the
radiotherapy treatment.
– The glomerular filtration rate (GFR) should be used
to assess the toxicity of the kidney, as recommended
by the National Kidney Foundation [9]. Early
changes in renal perfusion and GFR correlate with
an increased risk of late toxicity [2] and chronic
injury is unlikely if changes in GFR and perfusion
are not detected by 24 months after irradiation
[10,11].
– Significant technological advances in imaging offer
the possibility to study late responding normal
tissues using quantitative functional imaging instead
of a conventional histological analysis [12].
GFR can be estimated using serum creatinine levels
and estimating equations but in order to achieve a
higher degree of accuracy, a 51Cr-ethylenediamine tetra-
acetic acid (EDTA) clearance measurement should be
used. On the other hand, scintigraphy with Single Photon
Emission Computed Tomography (SPECT) can provide
greater detail regarding the relative distribution of kidney
function; kidney perfusion as indicated by uptake of 99mTc-
dimercaptosuccinic acid (DMSA), imaged with scintig-
raphy, has been shown to correlate with relative regional
function [13,14]. Sequential GFR measurements using
the 51Cr-EDTA clearance and SPECT imaging undertaken
before, during and after radiotherapy, allows observation of
regional functional changes in the kidney over time and
these changes can be correlated with the radiation dose
delivered during radiotherapy.
In order to quantify the relationship between radiation
dose delivery and kidney response, methods are required
that will allow the registration of the estimated three-
dimensional (3D) radiotherapy dose distribution to the
regional changes in kidney function, indicated by changes
in DMSA uptake [15]. In a SPECT/CT system [16], both
Computed Tomography (CT) and SPECT imaging is un-
dertaken on the one device with the patient in a single
position. This minimises any influence of patient motion
or physiological changes between the two imaging stud-
ies, allows simple fusion of the two resulting image sets
and also gives the anatomical reference to relate kidney
position. The CT component also facilitates attenuation
correction of the SPECT data which enables accurate
quantification of regional radiotracer uptake. Sequential
SPECT/CT studies can be spatially registered to planned
radiotherapy dose distributions, via registration of the
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for radiotherapy treatment simulation and planning.
Results from a pilot study at SGH are shown on Figure 1.
Study hypotheses
An assessment of changes in total kidney function (using
GFR measurement), regional kidney functional change
(using SPECT imaging) and their correlation with radio-
therapy dose delivery is within the means of currently
available imaging, therapy and computational technol-
ogy. The hypotheses being tested in RAPRASI are:
– Temporal variations in SPECT images of the kidneys
correlate with patterns of radiation dose delivery in
the kidneys.
– Models of kidney response developed from
SPECT-response studies can be used to predict
changes in kidney function as a result of radiation
therapy.
The principal aim of RAPRASI is to obtain a better
understating of kidney response when a patient is receiv-
ing radiotherapy for an upper-abdominal cancer. This
will involve monitoring the spatial and temporal changes
in kidney function for correlation with delivered three-
dimensional radiation dose distribution. A more precise
dose-volume response model for kidney will not only
improve our current understanding but may permit further
optimisation of radiation therapy techniques for upper-
abdominal tumours.
Methods/design
Study design and schedule
RAPRASI is a clinical research study for participants
with upper gastrointestinal malignancies (without meta-
static disease) and who have controlled and stable kidney
function. Radiotherapy treatment technique is according
to local departmental protocols. Participants are being re-
cruited as they present to the Department of RadiationFigure 1 A preliminary qualitative example. Sample patient data from a
are the outlines of the kidneys. a) Planned radiotherapy dose distribution (
(pre-treatment) SPECT intensity distribution (red - high activity, blue – low
in the high-dose region.Oncology, Sir Charles Gairdner Hospital (SCGH) in Perth,
Australia, and to the Department of Radiation Oncology,
Peter MacCallum Cancer Centre (PMCC) in Melbourne,
Australia. The protocol has been approved by both institu-
tional ethics committees. All patients are required to give
written informed consent.
In addition to a baseline visit, timed to coincide with
participants having a CT scan for the purpose of radio-
therapy simulation, participants will have follow-up visits
at 4, 12, 26, 52 and 78 weeks subsequent to the first
radiotherapy treatment fraction. On each occasion they
will undergo: a sequential 99mTc-DMSA SPECT/CT (sim-
ultaneous SPECT and CT images), a GFR measurement
(51Cr-EDTA clearance), a full blood count and assessment
of blood urea and electrolytes.
The timing of SPECT/CT scans is intended to reveal
i) acute and sub acute changes in total kidney function
(GFR measurement) before and following radiotherapy,
ii) information on kidney positioning before and following
radiotherapy, and iii) the time-dependence of changes in
regional kidney function and position (SPECT/CT scans)
before and following treatment.
Inclusion criteria
– Males or females older than 18 years of age.
– Histologically/cytologically proven upper GI
adenocarcinoma.
– Signed written informed consent provided to
participate in the study.
– Radical radiotherapy (dose > 40 Gy in 4 weeks)
being prescribed to an upper abdominal site that
will involve incidental radiation of one or both
kidneys.
– Loco regional staging of primary disease will have
been undertaken with dual phase (arterial and
portal) spiral CT.
– Serum creatinine ≤150 μmol/L.
– Performance status is ECOG grade 0, 1 or 2 [17].pilot study at SCGH. The images are coronal slices, the grey shapes
yellow 45 Gy to black 0 Gy) and kidney volumes. b) Baseline
activity). c) 12-week post treatment SPECT showing reduced perfusion
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– Major co-morbid illnesses that, in the opinion of the
investigator, would prevent the patient undergoing
planned SPECT/CT scans during the first year
following treatment.
– Evidence of metastatic disease.
– Significant loss of bodyweight (>15% weight loss
since diagnosis).
– Inadequate bone marrow function to undergo
planned therapy.
– Previous drug-induced nephrotoxicity and/or
planned treatments that are likely to cause
drug-induced nephrotoxicity.
– Previous abdominal radiotherapy.
– Pregnancy or lactation.Data collection and quality assurance
This study will be conducted according to the Human
Research Ethics Committee (HREC)-approved study pro-
tocol and the ‘Note for Guidance on Good Clinical Prac-
tice (CPMP/ICH/135/95) annotated with TGA comments’
(Therapeutic Goods Administration DSEB July [18]. The
study will be performed in accordance with the NHMRC
‘National Statement on Ethical Conduct in Human Re-
search’ (© Commonwealth of Australia 2007) and the
ethical principles within the ‘Declaration of Helsinki’
(Revised 1996) [19].
Sir Charles Gairdner Hospital will act as the sponsor of
this study at both the Peter MacCallum Cancer Centre and
Sir Charles Gairdner Hospital in Perth, Western Australia.
Standard medical care (prophylactic, diagnostic and thera-
peutic procedures) remains the responsibility of the pa-
tient’s treating physician.
The investigator is responsible for ensuring that no
participant undergoes any study related examination or
investigations prior to obtaining written informed consent.
The investigator will explain the aims, methods, possible
benefits and potential hazards before the participant gives
consent. The participant will be given sufficient time to
read the documentation, understand the project and have
any questions addressed prior to signing the consent form.
The participants will be advised that they have the right to
withdraw their consent to participate at any time without
any consequences.
Participant confidentiality will be protected at all times.
In any resulting publication or presentation, no patients
will be identified.
Records will be retained for 15 years post study comple-
tion in a locked facility, in accordance with TGA require-
ments. Access to participant study records will be limited
to treating clinician, chief investigator, his/her nominated
co-investigators and the local study co-ordinators.Collation of data will yield the following for each
participant:
– Local kidney function/response to therapy: regional
change in SPECT signal intensity: from baseline to 4 weeks post start of radiotherapy
 from baseline to 12 weeks post start of radiotherapy
 from baseline to 26 weeks post start of radiotherapy
 from baseline to 52 weeks post start of
radiotherapy
 from baseline to 78 weeks post start of
radiotherapy
– Planned 3D Regional radiation dose distributions
intended to be experienced during radiation treatment.
– Kidney function measure: GFR at baseline, 4, 12, 26,
52 and 78 weeks.
– Indication of existing and acquired co-morbidities.
– Information on adjuvant treatments.
GFR measurements using the 51Cr-EDTA clearance
and Digital Imaging and Communication in Medicine
(DICOM) formatted SPECT/CT images will be obtained
on Siemens Symbia T6 SPECT/CT scanners located in the
Department of Nuclear Medicine at SCGH and the Centre
for Molecular Imaging at the PMCC. These images in-
volve pre-injection of approximately 185 MBq of 99mTc-
DMSA (Radpharm DMS 1987/1), providing 128x128 pixel
attenuation-corrected images reconstructed at approxi-
mately 5 mm pixel resolution. SPECT images are auto-
matically registered to CT taken on the same device
(6 slice helical CT scanner), with image settings sufficient
for organ definition and bone matching with minimal ra-
diation dose (typically 130 kV, 80-100 mA, 5 mm slice
thickness). SPECT pixel intensity values will be normal-
ised according to calibration images obtained on the scan-
ner during monthly quality-assurance checks. SPECT data
will be reconstructed using an ordered subset expecta-
tion maximization (OSEM) algorithm incorporating CT
attenuation data.
Treatment plan data (images, structures, beam defini-
tions, dose-volume data, and 3D dose distribution) will
be exported in DICOM-RT format from the Treatment
Planning System. (CMS XiO at SCGH, Varian Eclipse at
PeterMac). Digitally reconstructed radiographs (DRRs)
will be generated indicating local bony anatomy (upper pel-
vis, spine, ribs) and the location of kidneys from the plan-
ning CT. Variation in kidney position relative to local bony
anatomy is of the order of SPECT image resolution [20,21].
Patient localisation will initially be to external marks, with
on-line positioning then corrected according to localisation
images spatially matched to the DRRs. Localisation images
will be obtained either with the Brainlab Exactrac system
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aging system (3D positioning) [23]. Applied patient shifts
will be recorded together with localisation images. Where
possible, kidney position will be identified on the localisa-
tion images for comparison with planned kidney outlines,
as per standard departmental practice.
It is anticipated that all participant data will be utilized
in the final analysis provided that each participant com-
pletes at least the baseline (pre-radiotherapy) and first
SPECT/CT scan at 4 weeks post start of radiotherapy. If
a participant commences radiotherapy (i.e. completes the
baseline SPECT/CT scan) but withdraws consent mid-
treatment or is unable to complete any further SPECT/
CT scans, then the data for that participant will be ex-
cluded from the final analysis.
Data relating to co-morbidities and concurrent treat-
ments, including adjuvant chemotherapy, known to influ-
ence kidney toxicity [2], will be extracted from participant
notes.
Statistical considerations
A target of 30 complete participant datasets has been set
based on an assessment of anticipated patient numbers,
recruitment and attrition rates, together with a power
calculation of the number of datasets required to indi-
cate a statistically significant variation in SPECT image
intensity. A clinically significant difference would be a
reduction of 20% from baseline to a follow-up imaging
study [5]. In order to detect a conservative estimate of a
10% reduction, where the measurement error is 20% we
would require a sample size of 33 (using a paired t-test
with alpha = 0.05 and power = 80%; detecting 10.5% with
30 patients which is sufficient). With an anticipated 20%
non-completion/attrition rate, allowance will be made for
up to 40 recruited patients. Given the intensive data ana-
lysis required per patient dataset in this study, 30 datasets
represents an upper-limit in terms of manageability.
Data analysis
To correlate the patterns of change in SPECT signal with
time relative to delivered dose distributions, SPECT sig-
nal intensity will be used as a measure of local renal
function – a change in this measure is an indication of
‘renal response’. This response needs to be correlated
with regional radiation dose distribution. Planned 3D ra-
diation dose distributions will be digitally registered with
kidney functional changes in order to generate dose re-
sponse models. The planning CT will be registered to
the initial SPECT/CT data for definition of baseline kid-
ney location and function. Subsequent SPECT/CT data
(intensity-normalised according to administered nuclide
activity) will be registered both using bone anatomy as
well as SPECT intensity distribution providing registra-
tion of radiation dose distribution and SPECT signal. Allimaging shall be performed with the patient in the same
position on a flat-topped couch, allowing quantification of
changes in kidney positioning in the abdomen relative
to the planned dose distribution. Co-registrations will be
made using the Velocity AI software [24]. Velocity’s de-
formable image registration will allow subsequent SPECT
images to be deformable registered to the baseline SPECT/
CT, on the basis of both CT anatomy and SPECT signal,
and for all co-registered data sets to be deformable regis-
tered to the planned 3D dose distribution. This will allow
subsequent SPECT images to be deformable registered to
the baseline SPECT/CT, on the basis of both CT anatomy
and SPECT signal, and all co-registered data sets to be de-
formable registered to the planned 3D dose distribution
(or vice-versa), exported from the Treatment Planning Sys-
tem in DICOM-RT format. Applying these methods to
data collected during the RAPRASI study will allow accur-
ate spatial registration of regional changes in SPECT signal
to planned radiotherapy dose. The method of registration
to obtain correlated SPECT/dose is shown on Figure 2.
This subsequent analysis of co-registered dose and
image data will be undertaken in several ways:
i. Methods will be developed to assess dose-response
correlations as a function of spatial position across each
kidney (sampled at varying resolutions). Kidney
volumes will be uniformly divided into regions on the
three-dimensional (3D) grid defining image and
spatially-registered radiation dose. t-tests and Wilcoxon
signed-rank tests will be undertaken to determine
regions with significantly different mean SPECT-signal
intensities between time-points for each study
participant. Mixed modelling with repeated measures
(and random subject effect) will be conducted across
all participant sets to examine the correlation of local
radiation dose with SPECT signal changes, generating a
map of dose-response change across all kidney
volumes. Given a significant correlation, this will be
extended to incorporate any revealed patterns of
co-morbidity or adjuvant therapy as categorical
variables.
ii. Dose-response correlations will then be examined
according to structural and functional regions. Analysis
i. will be repeated, but with regions defined according
to kidney structure, with medulla, renal artery and
cortex regions treated independently. This will also
involve cross-correlation between these regions to
examine inter-play that is likely to arise due to the
influence of radiation effects on vascular structures.
iii. Spatio-temporal mathematical models of functional
kidney dose-response will be implemented to relate
regional kidney irradiation to the primary measure
of total kidney function, GFR. These models,
including percolation theory [25] and the critical
Method of registration for each SPECT/CT scan to obtain correlated SPECT/dose information
Baseline SPECT / CT Planning CT, plan and 
dose distribution
Follow -up SPECT / CT












Figure 2 Diagram of the co-registration method.
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will utilise the 3D radiotherapy dose distribution (both
across each kidney and across individual functional
regions) to fit model parameters using maximum
likelihood estimation (MLE) methods. The statistical
assessment of fitting will be made by assessment of
parameter confidence intervals, and by undertaking
an F-test of the residual sums-of-squares from
MLE against that from MLE for a simple linear
(single-parameter) dose-response model.
iv. An export of co registered dose and SPECT
information will be made for regions defined by whole
kidneys, separately-identified medulla and cortex,
baseline-image functional regions, and at varying
spatial resolutions. Renal response patterns obtained
from variations in SPECT and GFR shall be fitted to
normal-tissue complication probability (NTCP) and
equivalent uniform-dose (EUD) models, as previously
undertaken by CI’s using estimated parameters [27,28].
Response indicators can be related to dose volume
histogram (DVH) and dose-function histogram (DFH)
data by maximum likelihood fitting to the parametric
NTCP/EUD models. For this purpose, the freely
available DREES code [29], developed in Matlab, will
be utilised. Separate analyses will be undertaken using
acute changes in SPECT signal (< 12 week images) as
well as the long-term changes indicated by images
taken at 52 or 78 weeks post-radiotherapy.Examination of the predictive nature of response models
will be made by establishing parameters based on the first
20 patient data sets, and utilising the models to predict
SPECT signal changes on the subsequent 10 patients. In
order to minimise parameter uncertainties however, final
parameter values will be based on data for all patients.
Ethics
The RAPRASI study has ethics approval from the HREC
at Sir Charles Gairdner Group, The University of Western
Australia in Perth, and the Peter MacCallum Cancer Centre
in Melbourne, Australia. The trial is registered with the
Australian New Zealand Clinical Trials Registry: ACTRN
12609000322235.
Discussion
RAPRASI is a unique study combining functional radio-
logical imaging with radiotherapy dose delivery for the
assessment of regional radiation-induced kidney toxicity.
The study focuses on a patient cohort which is poorly
represented in clinical studies and for whom outcomes
are known to be poor. Modern radiation therapy utilises
intensive calculation processes and digitally driven beam
delivery technologies to sculpt dose distributions in ways
that were not previously possible. To take proper advantage
of this technology it is necessary to understand how normal
tissues are expected to respond to highly variable radiation
dose distributions and how radiation dose may be sculpted
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tient or the desired tumour dose. The information gained
from the RAPRASI study, including models that allow pre-
diction of temporal changes in kidney toxicity, will add to
our current understanding of partial kidney radiation dose
response to improve outcomes (including maximizing the
preservation of function) of kidney dose response and toler-
ance to radiation.
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